Complete surgical resection represents the only potentially curative treatment for biliary tract cancer (BTC). Even after curative intent (R0) resection, the 5-year survival rate is low. Optimisation of post-operative adjuvant therapy is imperative. Data on prognostic factors for BTC are rare. Now that adjuvant chemotherapy is the standard of care, predictive markers are of importance.

The primary objective of this study is to evaluate the impact of gemcitabine and cisplatin compared to standard of care on disease-free survival (DFS) in patients with operable BTC. Within the current trial, tumour tissue will be collected together with the clinical data for translational research.


Study Chair

Dr Jennifer Shannon
Nepean Cancer Centre


Download materials

Download the full abstract

Download the study schema

Study schema